Dr. Mitchell Finer serves as a Strategic Advisor for ElevateBio and will focus his efforts on changing the way medicine is practiced through the development of ex vivo and in vivo gene edited products leveraging Life Edit's RNA guided nuclease and base editing platform. He is a co-founder of ElevateBio and previously served as the Company’s President of Research & Development and as Chief Executive Officer of Life Edit Therapeutics. Additionally, Dr. Finer is  an executive partner at MPM Capital.

Dr. Finer led ElevateBio’s R&D efforts, and was instrumental in the scaling of its technologies, expanding of its manufacturing capabilities and capacity, and driving the Company’s growth as a technology-driven organization. Prior to joining ElevateBio, he served as Chief Scientific Officer of Bluebird Bio, where he led the team that conceived of and developed three approved products: Abecma for the treatment of multiple myeloma, Zynteglo for the treatment of beta thalassemia and Skysona for the treatment of childhood cerebral adrenoleukodystrophy. He has served as founder, executive officer or board member at multiple cell therapy, gene therapy and regenerative medicine companies over the last 33 years, including Adverum Biotechnologies, Bluebird Bio, Coda Biotherapeutics, Cell Genesys, the Gencell division of Aventis Pharma (now Sanofi), Genteric, Inc., Intracel Corporation, Novacell (now Viacyte, acquired by Vertex), Oncorus, Inc., Semma Therapeutics, Turmeric Acquisition Holdings, and TCR2 Therapeutics.

His efforts have spanned discovery through market launch of cell gene therapy and regenerative medicine products in the U.S., Europe and Asia. He has also worked on many of the innovations for manufacture of these products.